Company Overview and News

CONE Midstream Partners' (CNNX) CEO John Lewis on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the CONE Midstream Partners CNNX Third Quarter Operating and Financial Results Conference Call and Webcast. All participants are currently in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions [Operator Instructions]. Please also note this event is being recorded.

CONE Midstream Partners: 25.3% ROIC Or 9.2% ROIC? It Doesn't Matter

2017-10-12 seekingalpha
Current unit price collapse is from investor uncertainty and not a lack of earnings or distribution growth potential. When this uncertainly clears, shareholder will be amply rewarded.

CONE Midstream: Simply Trading Too Cheap Based On Sponsor Fears

2017-07-01 seekingalpha
Concerns over peakiness in natural gas production have lingered for years; thus far, skeptics have been proven wrong.

Noble Midstream to Acquire Interest from Noble Energy (NBL)

2017-06-22 zacks
Noble Energy, Inc. (NBL - Free Report) and Noble Midstream Partners LP (NBLX - Free Report) signed a definitive agreement, as per which the latter will acquire additional interests worth $270 million in Colorado River DevCo LP and Blanco River DevCo LP from the former. Notably, Noble Midstream is a growth-oriented master limited partnership formed by Noble Energy to own, operate, develop and acquire domestic midstream infrastructure assets.

Total S.A. (TOT) Hits 52-Week High on Steady Performance

2017-05-22 zacks
TOTAL S.A. (TOT - Free Report) , an integrated oil and gas company has hit a new 52-week high of $54.34 during May 19 trading session before closing a tad lower at $53.97. The stock has delivered a one-year return of about 19.5% compared with the Zacks categorized Oil and Gas - Integrated - International industry’s gain of 12.3%. Over the past 52 weeks, TOTAL’s share price has ranged from a low of $44.

Natural Gas Slips on Larger-than-Expected Stock Build

2017-05-22 zacks
The U.S. Energy Department's weekly inventory release showed a bigger-than-expected increase in natural gas supplies, which had investors concerned and created downward pressure on prices.

U.S Rig Count Crosses 900 for First Time in 2 Years

2017-05-22 zacks
Oil field services firm Baker Hughes Inc. (BHI - Free Report) recently reported the rig count for the week ended May 19, 2017.

Quantum Energy, Inc. Acquires 100% of Quantum Native Processing Partners, LLC; Names Robert L. Monday as CEO

2017-05-11 marketwired
TEMPE, AZ--(Marketwired - May 11, 2017) - Refinery and energy processing developer Quantum Energy, Inc. (OTC PINK: QEGY) today announced that it now owns 100% of Quantum Native Processing Partners, LLC (QNPP) having acquired the 50% ownership interest from Native Son Refinery, Inc. (NSR). QNPP was formed by Quantum and NSR as a 50/50 joint venture in 2015 and Quantum has now acquired the NSR 50% interest to own 100% of QNPP.

Dominion Energy Processing Group, Inc. Announces Refinery Offtake Signing

2017-04-06 marketwired
TEMPE, AZ--(Marketwired - Apr 6, 2017) - Refinery and energy processing developer Quantum Energy, Inc. (OTC PINK: QEGY) today announced that its Canadian subsidiary, Dominion Energy Processing Group, Inc., has signed a Letter of Intent with FHQ Developments Ltd, a development company of the File Hills Qu'Appelle Tribal Council. FHQTC represents more than 14,000 First Nation citizens in eleven member First Nations communities in the province of Saskatchewan.

Quantum Energy, Inc. Files S-1 Registration Statement

2017-03-08 marketwired
TEMPE, AZ--(Marketwired - Mar 8, 2017) - Refinery and energy processing developer Quantum Energy, Inc. (OTC PINK: QEGY) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a follow on public offering of its common stock in a Primary Offering as well as a Secondary Offering of existing security holders. The shares of common stock to be sold in the Primary Offering will be offered directly by the Company without the use of an underwriter.

Quantum Resources to lift cash balance

Quantum Resources (ASX:QUR) has been granted a trading halt by the ASX, pending details of a capital raising.

Quantum Energy, Inc. Stoughton Refinery Update

2017-02-22 marketwired
TEMPE, AZ--(Marketwired - Feb 22, 2017) - Refinery and energy processing developer Quantum Energy, Inc. (OTC PINK: QEGY) issued the following shareholder update on recent corporate activities for the Dominion Energy Processing Group, Inc. (DEPGI) refinery project in Stoughton, Saskatchewan:

U.S. IPO Weekly Recap: FRAC Pops 14% In First IPO Of 2017, And 10 Others Launch

2017-01-21 seekingalpha
The 2017 IPO market is off to a stellar start. Oilfield services provider Keane Group became the year's first IPO when it raised $508 million - 69% more than anticipated - and popped 14% on Friday. Rising oil prices have brought back the energy sector in full force: Last year's first energy IPO didn't arrive until September. The IPO calendar also filled up with 10 new launches, more than any week since July 2015.

Quantum Energy, Inc. Shareholder Update

2016-12-14 marketwired
TEMPE, AZ--(Marketwired - Dec 14, 2016) - Refinery and energy processing developer Quantum Energy, Inc. (OTC PINK: QEGY) issued the following shareholder update on recent corporate activities for the Dominion Energy Processing Group, Inc. (DEPGI) refinery development project in Stoughton, Saskatchewan:

CORRECTION - Quantum Energy Canadian Refinery Site Under Contract

2016-12-07 marketwired
TEMPE, AZ--(Marketwired - Dec 7, 2016) -  In the news release, "Quantum Energy Canadian Refinery Site Under Contract" issued earlier today by Quantum Energy, Inc. (OTC PINK: QEGY), we are advised by the company that the figure in the second sentence of the first paragraph should read "320 acres" rather than "480 acres" as originally issued. Also, the contact information was changed to: Quantum Energy, Inc.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...